查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1370942

治疗疫苗市场 - 2018-2028 年全球产业规模、份额、趋势、机会与预测，按产品、技术、地区、竞争细分

Therapeutics Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product, By Technology, By Region, Competition
出版日期: | 出版商: TechSci Research | 英文 178 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年全球治疗性疫苗市场估值为 278.1 亿美元，预计在整个预测期内将实现强劲增长，实现 9.68% 的复合年增长率 (CAGR)，到 2028 年达到 483.2 亿美元。一种特定类型的疫苗，旨在治疗或减轻现有疾病，而不仅仅是预防疾病。与向健康个体注射以预防未来感染的传统预防性疫苗不同，治疗性疫苗是注射给那些已经受到疾病影响的人。目的是激活免疫系统，更有效地针对和对抗疾病。人们越来越认识到治疗性疫苗对健康的益处，预计将对全球市场的扩张产生正面影响。

主要市场驱动因素：

市场概况
预测期 2024-2028
2022 年市场规模 278.1亿美元
2028 年市场规模 483.2亿美元
2023-2028 年复合年增长率 9.68%
成长最快的细分市场 自体疫苗
最大的市场 北美洲

1. 疾病负担的增加推动市场成长：

包括癌症、慢性感染、自体免疫疾病和神经退化性疾病在内的各种疾病负担的不断增加，是全球治疗性疫苗市场的主要驱动力。随着越来越多的人受到这些疾病的影响，对治疗性疫苗等创新治疗解决方案的需求不断增加。这些疫苗提供了一种解决根本原因的替代方法，其潜在益处超出了现有治疗方法。

2.免疫学的进步推动市场成长：

免疫学的进步透过促进开发更有针对性和更有效的治疗性疫苗，在推动全球治疗性疫苗市场向前发展方面发挥关键作用。增强对免疫系统功能的了解有助于疫苗的设计和优化。这些知识对于治疗性疫苗尤其重要，治疗性疫苗旨在引发针对癌细胞或慢性感染病原体等致病因子的免疫反应。

3. 医疗保健支出增加：

医疗保健支出的增加极大地促进了全球治疗性疫苗市场的扩张。更高的医疗支出支持医学研究和开发，从而推动治疗性疫苗的进步。强而有力的临床试验计画对于将新疫苗推向市场至关重要，增加资金可以促进这些试验。充足的资金也促进研究机构、製药公司和学术中心之间的合作，推动治疗性疫苗开发的创新。

主要市场挑战：

1. 科学复杂性：

由于科学的复杂性，设计和开发有效针对特定疾病的疫苗的复杂性提出了巨大的挑战。与免疫系统、疾病特征和疫苗机制相关的各种因素导致了这种复杂性。疾病特异性疫苗设计、个人免疫系统变异以及合适抗原的选择是疫苗开发的挑战。

2. 开发时间长：

漫长的开发时间阻碍了新疫苗在市场上的快速供应。这种延迟会影响患者获得可能挽救生命的治疗，并使竞争公司更快推出类似产品，这可能导致错失市场机会。进展迅速或治疗窗口期关键的疾病尤其受到影响。

3. 製造挑战：

製造复杂性影响治疗性疫苗的生产、品质和可扩展性。确保一致的产品品质和克服大规模製造中的挑战至关重要。生产过程的可变性会影响疫苗的功效和性能。某些治疗性疫苗可能需要专用设备和设施，这给生产带来了挑战。

主要市场趋势：

1. 奈米技术与药物传输：

奈米技术和药物传输创新是全球治疗性疫苗市场的主要趋势，提供了增强疫苗有效性和标靶输送的解决方案。奈米技术可以设计新型疫苗配方，提高稳定性、生物利用度和免疫反应。奈米颗粒可以模仿病原体或以更有效地活化免疫系统的方式呈现抗原，可能导致更强、更持久的免疫反应。

2. 细分洞察：

自体免疫疾病疫苗因其在这些复杂条件下调节免疫反应的潜力而占据市场主导地位。然而，临床试验中的挑战、可变的疾病进展以及现有治疗方法的竞争影响了自体免疫疾病疫苗的开发。

3. 技术洞察：

由于更容易製造、标准化和安全性，同种异体疫苗比自体疫苗具有优势。同种异体疫苗可以更大量地生产并且更广泛地使用，从而推动其在市场上的主导地位。

区域见解：

1. 北美：

由于持续的癌症流行、研发支出的增加以及健康维护意识的增强，预计北美市场将会成长。该地区癌症的流行可能会推动对治疗性癌症疫苗的需求。

2.欧洲：

在其强大的生物製药产业、成熟的製药公司和研究机构的推动下，欧洲有望成为成长最快的治疗性疫苗市场。欧洲国家在临床试验和监管流程方面的经验支持疫苗开发，促进市场成长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球治疗疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（自体免疫疾病疫苗、神经疾病疫苗、癌症疫苗、传染病疫苗、其他）
    • 依技术分类（同种异体疫苗、自体疫苗）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图

第 6 章：北美治疗疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲治疗疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
  • 欧洲：国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章：亚太地区治疗疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章：南美洲治疗疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲治疗疫苗市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 依技术
  • MEA：国家分析
    • 南非治疗疫苗
    • 沙乌地阿拉伯治疗疫苗
    • 阿联酋治疗疫苗

第 11 章：临床试验分析

第 12 章：市场动态

  • 驱动因素与挑战

第 13 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 14 章：全球治疗疫苗市场：SWOT 分析

第15章：竞争格局

  • 商业概览
  • 技术产品
  • 最近的发展
  • 主要人员
  • SWOT分析
    • genus Inc.
    • Argos Therapeutic Inc.
    • Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
    • Dendreon Corp (Sanpower Group Co., Ltd.)
    • GlaxoSmithKline plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer, Inc.
    • Phio Pharmaceuticals Corp.
    • AstraZeneca PLC
    • BioNTech SE

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 4606

The Global Therapeutics Vaccine Market was valued at USD 27.81 Billion in 2022, and it is projected to experience robust growth throughout the forecast period, achieving a Compound Annual Growth Rate (CAGR) of 9.68% and reached USD 48.32 Billion through 2028. Therapeutics vaccines are a specific type of vaccine designed to treat or mitigate existing diseases rather than solely preventing them. In contrast to conventional preventive vaccines administered to healthy individuals to ward off future infections, therapeutic vaccines are given to those already affected by a disease. The purpose is to activate the immune system to more effectively target and combat the disease. The increasing awareness of the health benefits linked with therapeutic vaccines is expected to positively influence global market expansion.

Therapeutic cancer vaccines are in development to stimulate the immune system to identify and attack cancer cells. These vaccines can complement other cancer treatments like chemotherapy or radiation therapy. The objective is to enhance the body's inherent defense mechanisms to selectively target and eliminate cancer cells, potentially resulting in improved treatment outcomes. Therapeutic vaccines also hold promise in addressing chronic infections such as HIV, hepatitis B, and hepatitis C. These vaccines aim to amplify the immune response against the infectious agent, aiding the body in managing the infection and minimizing its adverse effects. The potential applications of therapeutic vaccines could expand with advancements in medical research and technology. However, their effectiveness and usage rely on rigorous scientific exploration and regulatory approval.

Key Market Drivers:

Market Overview
Forecast Period2024-2028
Market Size 2022USD 27.81 Billion
Market Size 2028USD 48.32 Billion
CAGR 2023-20289.68%
Fastest Growing SegmentAutologous vaccines
Largest MarketNorth America

1. Increasing Disease Burden Drives Market Growth:

The rising burden of various diseases, including cancer, chronic infections, autoimmune disorders, and neurodegenerative conditions, is a major driver for the global therapeutic vaccine market. With a growing number of individuals affected by these diseases, there is a heightened demand for innovative treatment solutions such as therapeutic vaccines. These vaccines offer an alternative approach to addressing underlying causes, offering potential benefits beyond existing treatments.

2. Advances in Immunology Fuel Market Growth:

Progress in immunology plays a pivotal role in propelling the global therapeutic vaccine market forward by enabling the development of more targeted and effective therapeutic vaccines. Enhanced understanding of immune system functions informs the design and optimization of vaccines. This knowledge is especially crucial for therapeutic vaccines, which aim to trigger immune responses against disease-causing agents like cancer cells or chronic infection pathogens.

3. Rising Healthcare Expenditure:

Increased healthcare spending significantly contributes to the expansion of the global therapeutic vaccine market. Higher healthcare expenditure supports medical research and development, leading to advancements in therapeutic vaccines. Robust clinical trial programs are essential for bringing new vaccines to market, and increased funding facilitates these trials. Adequate funding also fosters collaborations among research institutions, pharmaceutical companies, and academic centers, driving innovation in therapeutic vaccine development.

Key Market Challenges:

1. Scientific Complexity:

The intricate nature of designing and developing vaccines that effectively target specific diseases presents a substantial challenge due to scientific complexity. Various factors related to the immune system, disease characteristics, and vaccine mechanisms contribute to this complexity. Disease-specific vaccine design, immune system variability among individuals, and the selection of suitable antigens are among the challenges faced in vaccine development.

2. Long Development Timelines:

Long development timelines hinder the rapid availability of new vaccines in the market. This delay impacts patient access to potentially life-saving treatments and allows competing companies to advance similar products more quickly, potentially leading to missed market opportunities. Diseases with rapid progression or critical treatment windows are particularly affected.

3. Manufacturing Challenges:

Manufacturing complexities affect the production, quality, and scalability of therapeutic vaccines. Ensuring consistent product quality and overcoming challenges in large-scale manufacturing are critical. Variability in manufacturing processes can impact vaccine efficacy and performance. Specialized equipment and facilities may be required for certain therapeutic vaccines, contributing to production challenges.

Key Market Trends:

1. Nanotechnology and Drug Delivery:

Nanotechnology and drug delivery innovations are key trends in the global therapeutic vaccine market, offering solutions to enhance vaccine effectiveness and targeted delivery. Nanotechnology allows for the design of novel vaccine formulations that improve stability, bioavailability, and immune responses. Nanoparticles can mimic pathogens or present antigens in ways that activate the immune system more effectively, potentially leading to stronger and longer-lasting immune responses.

2. Segmental Insights:

Autoimmune disease vaccines dominate the market due to their potential to modulate immune responses in these complex conditions. However, challenges in clinical trials, variable disease progression, and competition from existing treatments impact vaccine development for autoimmune diseases.

3. Technology Insights:

Allogeneic vaccines hold an advantage over autologous vaccines due to easier manufacturing, standardization, and safety. Allogeneic vaccines can be produced in larger quantities and are more widely available, driving their dominance in the market.

Regional Insights:

1. North America:

The North American market is anticipated to grow due to the ongoing cancer epidemic, increasing R&D spending, and growing awareness of health maintenance. The prevalence of cancer in the region will likely drive the demand for therapeutic cancer vaccines.

2. Europe:

Europe is poised to be the fastest-growing market for therapeutic vaccines, driven by its robust biopharmaceutical industry, established pharmaceutical companies, and research institutions. European countries' experience in clinical trials and regulatory processes supports vaccine development, contributing to the growth of the market.

Key Market Players

  • Genus Inc.
  • Argos Therapeutic Inc.
  • Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
  • Dendreon Corp (Sanpower Group Co., Ltd.)
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Phio Pharmaceuticals Corp.
  • AstraZeneca PLC
  • BioNTech SE

Report Scope:

In this report, the Global Therapeutics Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Therapeutics Vaccine Market, By Product:

  • Autoimmune Disease Vaccines
  • Neurological Disease Vaccines
  • Cancer Vaccines
  • Infectious Disease Vaccines
  • Other

Therapeutics Vaccine Market, By Technology:

  • Allogeneic Vaccine
  • Autologous Vaccine

Therapeutics Vaccine Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Therapeutics Vaccine Market.

Available Customizations:

  • Global Therapeutics Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Therapeutics Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Other)
    • 5.2.2. By Technology (Allogeneic Vaccine, Autologous Vaccine)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Market Map

6. North America Therapeutics Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Therapeutics Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Therapeutics Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Therapeutics Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology

7. Europe Therapeutics Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Therapeutics Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
    • 7.3.2. United Kingdom Therapeutics Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
    • 7.3.3. Italy Therapeutics Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
    • 7.3.4. France Therapeutics Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Therapeutics Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology

8. Asia-Pacific Therapeutics Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Therapeutics Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Therapeutics Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Therapeutics Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Therapeutics Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Therapeutics Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology

9. South America Therapeutics Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Therapeutics Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
    • 9.3.2. Argentina Therapeutics Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
    • 9.3.3. Colombia Therapeutics Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology

10. Middle East and Africa Therapeutics Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Therapeutics Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
    • 10.3.2. Saudi Arabia Therapeutics Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
    • 10.3.3. UAE Therapeutics Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology

11. Clinical Trial Analysis

12. Market Dynamics

  • 12.1. Drivers & Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Merger & Acquisition

14. Global Therapeutics Vaccine Market: SWOT Analysis

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Technology Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. genus Inc.
    • 15.5.2. Argos Therapeutic Inc.
    • 15.5.3. Celldex Therapeutic Inc. (Avant Immunotherapeutics, Inc.)
    • 15.5.4. Dendreon Corp (Sanpower Group Co., Ltd.)
    • 15.5.5. GlaxoSmithKline plc
    • 15.5.6. Merck & Co. Inc.
    • 15.5.7. Novartis AG
    • 15.5.8. Pfizer, Inc.
    • 15.5.9. Phio Pharmaceuticals Corp.
    • 15.5.10. AstraZeneca PLC
    • 15.5.11. BioNTech SE

16. Strategic Recommendations

17. About Us & Disclaimer